Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib

<br><strong>Background </strong>Pain is a core domain of psoriatic arthritis (PsA). This post hoc analysis evaluated time to pain improvement and the impact of baseline pain severity on pain response in patients with PsA receiving tofacitinib. <br><strong> Methods </...

Descripció completa

Dades bibliogràfiques
Autors principals:	de Vlam, K, Ogdie, A, Bushmakin, AG, Cappelleri, JC, Fleischmann, R, Taylor, PC, Azevedo, V, Fallon, L, Woolcott, J, Mease, PJ
Format:	Journal article
Idioma:	English
Publicat:	BMJ Publishing Group 2021

Ítems similars

Median time to pain improvement in patients with psoriatic arthritis treated with tofacitinib
per: de Vlam, K, et al.
Publicat: (2018)

Baseline pain severity as a predictor of pain improvement following treatment with tofacitinib in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2018)

Identifying and quantifying the role of inflammation in pain reduction for patients with psoriatic arthritis treated with tofacitinib: a mediation analysis
per: de Vlam, K, et al.
Publicat: (2022)

Understanding mediators of pain reduction in psoriatic arthritis patients treated with tofacitinib: role of inflammation
per: Taylor, P, et al.
Publicat: (2019)

Identifying mediators of pain reduction in patients with psoriatic arthritis treated with tofacitinib: Role of inflammation associated with peripheral arthritis, enthesitis and skin disease
per: Taylor, PC, et al.
Publicat: (2020)

The effect of tofacitinib on residual pain in patients with psoriatic arthritis
per: Dougados, M, et al.
Publicat: (2020)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
per: Iain B McInnes, et al.
Publicat: (2020-02-01)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
per: Dougados, M, et al.
Publicat: (2022)

The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis
per: Maxime Dougados, et al.
Publicat: (2022-11-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
per: Gladman, DD, et al.
Publicat: (2022)

Itch as major mediator of effect of tofacitinib on health-related quality of life in psoriatic arthritis: a mediation analysis
per: Taylor, PC, et al.
Publicat: (2021)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in Phase 3 studies of tofacitinib
per: Coates, L, et al.
Publicat: (2021)

Pain and inflammation as mediators of tofacitinib treatment effect on fatigue in patients with ankylosing spondylitis: a mediation analysis
per: Kristensen, LE, et al.
Publicat: (2023)

Effectiveness of Tofacitinib in Patients Initiating Therapy for Psoriatic Arthritis: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
per: Philip J. Mease, et al.
Publicat: (2024-01-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
per: Taylor, P, et al.
Publicat: (2022)

Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
per: Daniela Graham, et al.
Publicat: (2021-04-01)

Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo
per: Dafna D. Gladman, et al.
Publicat: (2022-02-01)

Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib
per: Laura C. Coates, et al.
Publicat: (2021-03-01)

Relationships of dermatologic symptoms and quality of life in patients with psoriatic arthritis: analysis of two tofacitinib phase III studies
per: Peter C. Taylor, et al.
Publicat: (2022-07-01)

Measuring outcomes in psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2020)

Efficacy and Safety of Tofacitinib in Patients with Psoriatic Arthritis or Ankylosing Spondylitis by Cigarette Smoking Status
per: Alexis Ogdie, et al.
Publicat: (2024-09-01)

Pain and Inflammation as Mediators of Tofacitinib Treatment Effect on Fatigue in Patients with Ankylosing Spondylitis: A Mediation Analysis
per: Lars Erik Kristensen, et al.
Publicat: (2023-06-01)

Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance
per: Nash, P, et al.
Publicat: (2020)

Psoriatic arthritis
per: FitzGerald, O, et al.
Publicat: (2021)

Time to improvement of pain, morning stiffness, fatigue, and disease activity in patients with ankylosing spondylitis treated with tofacitinib: a post hoc analysis
per: Victoria Navarro-Compán, et al.
Publicat: (2024-05-01)

Inhibition of interleukin-17 in patients with oligoarticular psoriatic arthritis
per: Ogdie, A, et al.
Publicat: (2023)

Psoriatic arthritis - Tofacitinib as a new treatment
per: Marta Skorupska, et al.
Publicat: (2024-06-01)

Pain reduction in patients with rheumatoid arthritis receiving tofacitinib monotherapy with or without pain medication: A post hoc analysis of pooled data from phase 2, phase 3 and phase 3B/4 studies
per: Taylor, PC, et al.
Publicat: (2019)

Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
per: Philip J Mease, et al.
Publicat: (2019-06-01)

Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
per: Philip J Mease, et al.
Publicat: (2019-06-01)

Itch as the major mediator of the effect of tofacitinib on health-related quality of life in PSA: a mediation analysis
per: Taylor, P, et al.
Publicat: (2020)

Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs
per: Kevin L. Winthrop, et al.
Publicat: (2022-12-01)

Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib
per: Lars E. Kristensen, et al.
Publicat: (2023-02-01)

Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
per: Nash, P, et al.
Publicat: (2021)

Post-marketing safety surveillance of tofacitinib over 9 years in patients with psoriatic arthritis and rheumatoid arthritis
per: Burmester, GR, et al.
Publicat: (2023)

Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives
per: Ly K, et al.
Publicat: (2019-08-01)

Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies
per: Nash, P, et al.
Publicat: (2018)

Post-Marketing Safety Surveillance of Tofacitinib over 9 Years in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
per: Gerd R. Burmester, et al.
Publicat: (2023-07-01)

Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies
per: Peter Nash, et al.
Publicat: (2018-11-01)

Classification and outcome measures for psoriatic arthritis
per: Leung, Y, et al.
Publicat: (2018)